Allergic Rhinitis Market size was estimated at USD 15.4 billion in 2024 and is projected to attain USD 23.5 billion in 2037, surging at a CAGR of 3.6% during the forecast period i.e. 2025 to 2037. In 2025, the industry size of allergic rhinitis is assessed at USD 15.9 billion.
The allergic rhinitis industry is fostering significantly owing to the rising global incidences of allergic conditions. For instance, in April 2020, it was published in The LANCET Global Health that the cases of allergic rhinitis among children aged between 6-7 years were 11.3% and 24.4% in children aged between 13-14 years. In addition, there are rising environmental pollution, climate change, and increasing incidences of urbanization factors that raise the exposure levels to allergen agents and, therefore, to allergic rhinitis cases.
Increasing awareness of symptoms and treatment options has led to more individuals seeking to be diagnosed and treated. New pharmaceutical formulations such as novel antihistamines, intranasal corticosteroids, and biologic therapies that provide potentially better and safer profiles are responsible for fueling the market. For instance, in October 2024, GSK plc reported positive results from the phase III clinical trials ANCHOR-1 and ANCHOR-2. In this trial, depemokimab showed efficacy as well as safety in comparison to placebo in adults with CRSwNP. Furthermore, improved medical care accessibility in developing economies is also contributing to further expansion in the market.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
3.6% |
|
Base Year Market Size (2024) |
USD 15.4 billion |
|
Forecast Year Market Size (2037) |
USD 23.5 billion |
|
Regional Scope |
|
Route of Administration (Nasal & Others, Oral)
By 2037, nasal & others segment is expected to dominate over 55.3% allergic rhinitis market share. The growth is fostered by direct, local drug delivery, thus imparting a fast onset of action and greater efficacy in symptom control. For instance, in September 2022, Hikma Pharmaceuticals PLC and Glenmark Pharmaceuticals Ltd. collaboratively produced a nasal spray, Ryaltris. This is approved by the FDA and is effective for children aged between 12 years and over and acts within 15 minutes of the nasal problems. Ease of use, convenience, and relatively low-cost add to the dominance of the nasal route. Moreover, patient preference for self-administration through nasal sprays further propels higher adoption in the market.
Type (Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Occupational Allergic Rhinitis)
The seasonal allergic rhinitis segment gains a significant proportion of the allergic rhinitis market due to the immense prevalence of pollen-related allergies, mostly during certain seasons, including spring and fall. Being seasonal, the disease causes episodic attacks resulting in a relatively frequent visit by the patients to their treating physicians, therefore supporting continuous demand in the market. For instance, in February 2024, Novartis announced that the US FDA has approved Xolair (omalizumab) for reducing allergic reactions, including anaphylaxis with IgE-mediated food allergy. Over-the-counter and prescription drugs differentiated strictly based on seasonal symptoms enhance the dominance of the segment.
Our in-depth analysis of the allergic rhinitis market includes the following segments:
|
Route of Administration |
|
|
Treatment |
|
|
Type |
|
North America Market Statistics
By 2037, North America allergic rhinitis market is anticipated to hold more than 45.5% share. The growth is stimulated owing to the increased indoor living and exposure to dust mites, pet dander, and other allergens. In addition, the in-built air conditioning systems with heating systems stimulate the circulation of allergens resulting in increased prevalence.
Canada allergic rhinitis market is anticipated to register considerable growth during the forecast period. The major characteristic of the Canada landscape for the allergic rhinitis market is the emerging demand for effective treatments as air pollution surges and climate change advances, coupled with a heightened awareness of environmental allergens more than ever. For instance, in August 2024, it was published that up to 20% of the general population in Canada is estimated to have a diagnosis of allergic rhinitis due to rising air pollution and changing environmental conditions.
The U.S. landscape is transforming through a shift towards even more personalized and convenient treatment options, such as SLIT and improved nasal sprays, further fueling the growth in the sector. In addition, the regulatory structure boosts the development of treatment options for allergic rhinitis. For instance, in March 2023, the U.S. FDA approved the ZAVZPRET, a nasal spray developed by Pfizer. This spray is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults.
Asia Pacific Market Analysis
Asia Pacific is the most rapidly growing region in the allergic rhinitis market, driven by the increasing pollutants in the air such as particulate matter and vehicular emissions. It fuels the cases of allergic rhinitis amongst the population thus increasing the need for timely diagnosis. In addition, the majority of the population in this region is inclusive middle-class which seeks affordable treatment options for allergic rhinitis.
The primary growth driver for the allergic rhinitis market in India is fueled by the all-around increasing urbanization, gradual aggravation of air pollution, and lifestyle changes that trigger a higher incidence of allergic conditions. For instance, in October 2024, it was published in the Economic Times that Bengaluru, with rapid urbanization and huge high-rise construction, has faced an all-year-long pollination allergy that has posed a health threat to its citizens. Environmental reduction in air quality and sudden climate changes have been separately aggravating this issue present at this point.
The allergic rhinitis market in China is evolving at a steady pace attributable to rising activities toward research into the root cause of allergic rhinitis and its treatments. For instance, in October 2024, it was published that researchers in China found that a change in the morphology of an immune receptor plays a significant role in allergic reactions. Such a discovery may bring new, useful insight into the development of allergy medicines. Moreover, the market is witnessing both expansion in treatment options and increasing demand for customized therapies with greater efficacy and fewer side effects.
The allergic rhinitis market is driven by a competitive landscape curated by the presence of well-established and emerging key players. The major participants in the market are diversifying their portfolios and focusing on innovating biological therapies for treating allergic rhinitis. In addition, the trend of treatments using advanced technologies and growing emphasis on personalized healthcare solutions is fueling the allergic rhinitis market expansion.
Here’s the list of some key players:
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?